# A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

> **NCT02637856** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 608 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT02637856
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-11
- **Primary completion:** 2019-05-03
- **Final completion:** 2019-05-03
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2020-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637856, "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02637856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*